Personalized Treatment for Coronary Artery Disease
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment for coronary artery disease?
Research shows that personalized medicine, which includes tailoring treatments based on individual characteristics like genetics and biomarkers, can improve patient outcomes. Although the cardiovascular field has not widely used genetic markers, using prognostic variables to identify likely responders has been a common practice, suggesting potential benefits for personalized treatment in coronary artery disease.12345
Is personalized treatment for coronary artery disease safe?
The safety of personalized treatment for coronary artery disease is not directly addressed in the available research articles. However, personalized medicine aims to tailor treatments to individual patients, potentially reducing adverse reactions by considering genetic and other personal factors.15678
How is the personalized treatment for coronary artery disease different from other treatments?
This personalized treatment for coronary artery disease uses a patient's unique biological information, such as genetic and clinical data, to tailor therapy specifically for them, unlike standard treatments that follow a one-size-fits-all approach. It leverages machine learning models to predict and improve health outcomes by identifying the best therapy for each individual, potentially extending the time before adverse events occur.146910
What is the purpose of this trial?
People with Coronary Artery Disease (CAD) have narrow or blocked arteries that supply blood to the heart. Reduced blood flow to the heart muscle from CAD can cause chest pain or aching, especially with exercise or activity. CAD can lead to weakening of the heart muscle or heart failure, and a higher risk of heart attack or death. Certain proteins in the blood, known as biomarkers, can be found in people with CAD. Higher levels of these biomarkers are associated with a greater risk of complications from CAD. The purpose of this study is to see if a customized treatment based on biomarkers will reduce the biomarker levels and lead to lower risk of complications from CAD.
Research Team
Arshed Quyyumi, MD
Principal Investigator
Emory University
Eligibility Criteria
Adults aged 21-90 with stable Coronary Artery Disease (CAD) or those who've had recent heart treatments can join. They must have certain levels of calcium in their arteries or visible atherosclerosis. Excluded are pregnant individuals, those planning heart procedures, severe heart failure patients, transplant recipients, and active cancer patients.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive customized treatment based on biomarker levels, including medication adjustments and lifestyle changes
Follow-up
Participants are monitored for safety and effectiveness after treatment, including measurements of BRS and adverse events
Treatment Details
Interventions
- Customized Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor